Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 14, 2020
- Accepted in final form November 3, 2020
- First Published January 6, 2021.
Author Disclosures
- José I. Fernández-Velasco, BSc (fernacho_vel{at}hotmail.com),
- Jens Kuhle, MD, PhD (jens.kuhle{at}usb.ch),
- Enric Monreal, MD (enrique.monreal{at}salud.madrid.org),
- Virginia Meca-Lallana, MD (virmeca{at}hotmail.com),
- José Meca-Lallana, MD, PhD (pmecal{at}gmail.com),
- Guillermo Izquierdo, MD, PhD (g.i.ayuso{at}gmail.com),
- Francisco Gascón-Giménez, MD (fgascongimenez{at}gmail.com),
- Susana Sainz de la Maza, MD (susana.sainzdelamaza{at}salud.madrid.org),
- Paulette E. Walo-Delgado, MD (paulettewalo{at}gmail.com),
- Aleksandra Maceski, PhD (aleksandra.maceski{at}unibas.ch),
- Eulalia Rodríguez-Martín, PhD (eulalia.rodriguez{at}salud.madrid.org),
- Ernesto Roldán, PhD (ernesto.roldan{at}salud.madrid.org),
- Noelia Villarrubia, PhD (noelia.villarrubia{at}salud.madrid.org),
- Albert Saiz, MD, PhD (asaiz{at}clinic.cat),
- Yolanda Blanco, MD (yblanco{at}clinic.cat),
- Pedro Sánchez, MD (pedro871{at}gmail.com),
- Ester Carreón-Guarnizo, MD, PhD (strcg_2{at}hotmail.com),
- Yolanda Aladro, MD (yolanda.aladro{at}salud.madrid.org),
- Luis Brieva, MD (brievaluis{at}hotmail.com),
- Cristina Íñiguez, MD (cinniguez{at}salud.aragon.es),
- Inés González-Suárez, MD (igonsua{at}gmail.com),
- Luis A. Rodríguez de Antonio, MD (luisalberto.rodriguez{at}salud.madrid.org),
- Jaime Masjuan, MD (jaime.masjuan{at}salud.madrid.org),
- Lucienne Costa-Frossard, MD (lucienne.costa{at}salud.madrid.org) and
- Luisa M. Villar, PhD
- José I. Fernández-Velasco, BSc (fernacho_vel{at}hotmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jens Kuhle, MD, PhD (jens.kuhle{at}usb.ch),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Bayer AG (2) Biogen (3) Celgene (4) Sanofi (5) Merck (4) Novartis (5) Roche
(1) Swiss National Research Foundation (320030_189140/1)
NONE
(1) ECTRIMS Research Fellowship Programme (2) University of Basel (3) Swiss MS Society (4) Progressive MS Alliance
NONE
NONE
NONE
NONE
NONE
NONE
- Enric Monreal, MD (enrique.monreal{at}salud.madrid.org),
NONE
NONE
Sanofi-Genzyme; Roche; Merck-Serono; Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Virginia Meca-Lallana, MD (virmeca{at}hotmail.com),
scientific advisory boards for Genzyme and Roche, and has received speaker honoraria from Sanofi-Aventis, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Biogen Idec and Terumo.
NONE
Genzyme, Sanofi-Aventis, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Biogen Idec and Terumo.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- José Meca-Lallana, MD, PhD (pmecal{at}gmail.com),
Dr. Jose E Meca-Lallana has received compensation for consulting services from Biogen-Idec, Bristol-Meyers-Squibb, Merck-Serono, Sanofi-Aventis, Roche and Teva Pharmaceutical Industries Ltd
NONE
Dr. Jose E Meca-Lallana has received speaker honoraria from Almirall, Biogen-Idec, Bristol-Meyers-Squibb, Merck-Serono, Novartis, Roche, Sanofi-Aventis and Teva Pharmaceutical Industries Ltd.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Guillermo Izquierdo, MD, PhD (g.i.ayuso{at}gmail.com),
Biogen-Idec, Roche, Novartis, Sanofi Genzyme, Merck Serono, Actelion,Janssen, Celgene and Teva.
NONE
NONE
NONE
NONE
NONE
NONE
Sanofi Genzyme, Roche, Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Francisco Gascón-Giménez, MD (fgascongimenez{at}gmail.com),
(1) Genzyme-Sanofi (2) Novartis (3) Roche (4)Merck (5)Biogen
NONE
(1) Genzyme-Sanofi, funding for travel and speaker honoraria (2) Novartis, funding for travel and speaker honoraria(3) Roche funding for travel and speaker honoraria (4)Merck funding for travel and speaker honoraria (5)Biogen funding for travel and speaker honoraria (6)Almirall funding for travel(7) Bayerfunding for local neurological meeting
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Susana Sainz de la Maza, MD (susana.sainzdelamaza{at}salud.madrid.org),
(1) Almirall (2) Biogen (3) Genzyme (4) Merck (5) Novartis (6) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paulette E. Walo-Delgado, MD (paulettewalo{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aleksandra Maceski, PhD (aleksandra.maceski{at}unibas.ch),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eulalia Rodríguez-Martín, PhD (eulalia.rodriguez{at}salud.madrid.org),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ernesto Roldán, PhD (ernesto.roldan{at}salud.madrid.org),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Noelia Villarrubia, PhD (noelia.villarrubia{at}salud.madrid.org),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Fondo para la Investigación Sanitaria from the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovación (Spain) and Fondo Europeo de Desarrollo Regional (FEDER), grant number: RD16/0015/0001, 2019-2021 (2)Fondo para la Investigación Sanitaria from the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovación (Spain) and Fondo Europeo de Desarrollo Regional (FEDER), grant number: PI18/00572, 2017-2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Albert Saiz, MD, PhD (asaiz{at}clinic.cat),
NONE
NONE
compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd, Novartis, Alexion,and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yolanda Blanco, MD (yblanco{at}clinic.cat),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pedro Sánchez, MD (pedro871{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ester Carreón-Guarnizo, MD, PhD (strcg_2{at}hotmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Yolanda Aladro, MD (yolanda.aladro{at}salud.madrid.org),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luis Brieva, MD (brievaluis{at}hotmail.com),
COMMERCIAL ENTITY: Bayer, Celgene, Merck, Biogen, Sanofi, Roche
NONE
COMMERCIAL ENTITY: Bayer, Celgene, Merck, Biogen, Sanofi, Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Institut de reserca de Lleida: IRBLLEIDA. Lleida University.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cristina Íñiguez, MD (cinniguez{at}salud.aragon.es),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Inés González-Suárez, MD (igonsua{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Luis A. Rodríguez de Antonio, MD (luisalberto.rodriguez{at}salud.madrid.org),
(1) Sanofi Aventis.
NONE
(1)Biogen Idec, travel grant.(2)Novartis, travel grant.(3)Almirall, travel grant, speaker honoraria.(4)Sanofi Aventis, travel grant, speaker honoraria.(5)Roche, speaker honoraria.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jaime Masjuan, MD (jaime.masjuan{at}salud.madrid.org),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lucienne Costa-Frossard, MD (lucienne.costa{at}salud.madrid.org) and
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
NONE
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
Editorial Board Member in American Journal of Psychiatry and Neuroscience
NONE
NONE
NONE
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa M. Villar, PhD
(1)Biogen (2)Novartis (3)Sanofi/Genzyme (4)Bristol Myers Squibb
NONE
(1)Biogen (2)Novartis (3)Sanofi/Genzyme (4)Bristol Myers Squibb (5)Merck (6)Roche.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Biogen (2)Merck (3)Sanofi/Genzyme (4)Roche
(1) ISCIII-Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER, "Otra manera de hacer Europa") RD16/0015/0002. Role: Collaborative research in MS. Years: 2017-2021; ISCIII-Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER, "Otra manera de hacer Europa").RD16/0015/0003. Role: Collaborative research in MS. Years: 2017-2021; ISCIII-Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER, "Otra manera de hacer Europa") PI18/00572. Role: Effect of anti-CD20 antibodies in the immunological mechanisms in MS. Years: 2019-2021.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Immunology Department (J.I.F.-V., P.E.W.-D., E.R.-M., E.R., N.V., L.M.V.), Ramon y Cajal University Hospital, Madrid, Spain; Neurologic Clinic and Policlinic (J.K., A.M.), Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Switzerland; Neurology Department (E.M., S.S.d.l.M., J.M., L.C.-F.), Ramon y Cajal University Hospital, Madrid; Neurology Department (V.M.-L., P.S.), La Princesa University Hospital, Madrid; Multiple Sclerosis and Clinical Neuroimmunology Unit (J.M.-L., E.C.-G.), Virgen de la Arrixaca University Hospital, Murcia; Multiple Sclerosis Unit (G.I.), Vithas Nisa Sevilla Hospital; Neurology Department (F.G.-G.), Valencia Clinic University Hospital; Center of Neuroimmunology (A.S., Y.B.), Neurology Department, Clínic of Barcelona Hospital, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Institut de Neurociències, Universitat de Barcelona; Neurology Department (Y.A.), Getafe University Hospital, Madrid; Neurology Department (L.B.), Arnau de Vilanova Hospital, Lleida; Neurology Department (C.Í.), Lozano Blesa Clinic University Hospital, Zaragoza; Neurology Department (I.G.-S.), Alvaro Cunqueiro Hospital, Vigo; Neurology Department (L.A.R.d.A.), Fuenlabrada University Hospital, Madrid, Spain.
- Correspondence
Dr. Villar villarluisa88{at}gmail.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.